The eligibility criteria were as follows: age ≥ 20 years; pathologically diagnosed NSCLC without driver gene alteration; ≤49% PD-L1 expression (determined using the 22C3 antibody; Dako North America, Carpinteria, CA/Agilent Technologies, Santa Clara, CA, USA) on tumor cells; patients with evaluable lesions using response evaluation criteria in solid tumors (RECIST) version 1.1 [27 (link)]; and patients treated with CIT or SEQ as first-line treatment during the eligible period. Patients who received ICI monotherapy as third-line or subsequent treatment and patients with an Eastern Cooperative Oncology Group performance status (ECOG-PS) of ≥2 at the start of first-line treatment were excluded.
22c3 antibody
Manufactured by Agilent Technologies
Sourced in United States
The 22C3 antibody is a laboratory-grade reagent used for the detection and quantification of specific proteins or other biomolecules in research and diagnostic applications. It functions as a highly specific binding agent that can be used in various analytical techniques, such as immunoassays. The 22C3 antibody provides a reliable and consistent tool for researchers and clinicians to investigate the presence and levels of target analytes in their samples.
Automatically generated - may contain errors
Lab products found in correlation
12 protocols using 22c3 antibody
1
NSCLC Immunotherapy Eligibility Criteria
2
PD-L1 expression assessment protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Baseline tumor biopsies were stored in formalin-fixed paraffin-embedded blocks. PD-L1 expression was evaluated using immunohistochemical staining with the 22C3 antibody (Dako, Glostrup, Denmark). PD-L1 expression was reported using the combined positive score (CPS) and tumor proportion score (TPS). CPS was defined as the number of PD-L1-positive cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells multiplied by 100. TPS was determined as the percentage of tumor cells with partial or complete staining relative to all tumor cells in the sample.
3
Molecular Profiling of Lung Cancers
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Most of the patients had undergone CT-guided needle aspiration for diagnosis. Once the diagnosis was confirmed pathologically, part of the sample was used for multiple gene detection, such as EGFR, ALK, C-Met, and K-RAS, the detection was performed using standard assay. The detection of PD-L1 was conducted according to the standard assay (Dako 22C-3 antibody), and the cutoff value for PD-L1 was set as 1%.
4
Genomic Profiling of NSCLC Patients Treated with PD-1/PD-L1 Inhibitors
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Twenty patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors in The Second Xiangya Hospital, Central South University who had genomic profiling of whole exome sequencing (WES) before treatment were included in our GloriousMed cohort (Supplementary Table S1
TMB was defined as the total number of somatic mutations per exome in megabases. PD-L1 staining was evaluated centrally by IHC using 22C3 antibody and an automated staining procedure developed by Dako. The percentage of PD-L1 expression was scored by a qualified pathologist in samples with a minimum of 100 viable tumor cells.
Objective response was assessed by investigator-assessed RECIST 1.1 criteria every 6 weeks (two cycles of ICB administration). The complete response (CR) or partial response (PR) was considered as responders, whereas patients with stable disease (SD) or progressive disease (PD) were considered as non-responders.
All patients collection and usage were in accordance with the principles of the Declaration of Helsinki and approved by the Institution Review Board of The Second Xiangya Hospital, Central South University. The written informed consent for sample acquisition was obtained from all patients. All data were deidentified.
TMB was defined as the total number of somatic mutations per exome in megabases. PD-L1 staining was evaluated centrally by IHC using 22C3 antibody and an automated staining procedure developed by Dako. The percentage of PD-L1 expression was scored by a qualified pathologist in samples with a minimum of 100 viable tumor cells.
Objective response was assessed by investigator-assessed RECIST 1.1 criteria every 6 weeks (two cycles of ICB administration). The complete response (CR) or partial response (PR) was considered as responders, whereas patients with stable disease (SD) or progressive disease (PD) were considered as non-responders.
All patients collection and usage were in accordance with the principles of the Declaration of Helsinki and approved by the Institution Review Board of The Second Xiangya Hospital, Central South University. The written informed consent for sample acquisition was obtained from all patients. All data were deidentified.
5
PD-L1 IHC Analysis in Xenograft Tumors
6
IHC-based PD-L1 Expression Evaluation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
PD-L1 detection was performed on surgically resected tissue specimens using the IHC method. After the surgical excision, the specimens were fixed with 10% formaldehyde and embedded in paraffin. Subsequently, the specimens were sectioned, antigen-repaired, and blocked, followed by the dropwise addition of PD-L1 antibody (22C3 antibody, Dako, USA). The PD-L1 expression level was determined based on the tumor proportion score (TPS), which represents the percentage of partially or completely membrane-stained tumor cells at any intensity. The PD-L1 expression of NSCLC was classified into either negative (<1% or absence of reactivity) or positive (≥1%) according to the TPS result [18] (link).
7
Evaluation of Esophageal Carcinoma Prognosis
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The depth of tumor invasion, lymph node metastasis, and surgical margin were evaluated according to the American Joint Committee on Cancer Criteria for esophageal carcinoma (12 (link)). The extent of the residual tumors was divided into four categories: grade 0, no evidence of viable tumor cells (pCR); grade 1, single cells or rare small groups of cancer cells (near-complete response); grade 2, residual cancer cells with evident tumor regression, but more than single cells or rare small groups of cancer cells (partial response); and grade 3, extensive residual cancer without evident tumor regression (poor or no response) (13 (link)). The postoperative pathological evaluation was carried out by two experienced pathologists. The expression of PD-L1 was examined using the Dako 22C3 antibody and counted based on a CPS.
8
PD-L1 Expression Evaluation in Tumour
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
PD-L1 expression was evaluated on tissue tumour with LDTs, established on a Benchmark Ultra system using a 22C3 antibody (DAKO monoclonal mouse anti human PD-L1). The results of PD-L1 expression have been returned as the percentage of PD-L1 positive cells (PPC), based on the total of viable tumour cells in the specimen. The following scores were used: PPC =0% (PPC0); PPC =1–49% (PPC1-49) and PPC ≥50% (PPC50).
9
PD-L1 Immunohistochemistry Evaluation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Standard 4-µm thick FFPE sections were subjected to IHC analysis using an anti-PD-L1 antibody (22-C3 antibody; Agilent, Santa Clara, CA, USA; dilution 1/100; Optiview DAB IHC detection kit, Roche, Switzerland) on a Ventana automated staining platform (BenchMark ULTRA, Tucson, AZ, USA). The tumour proportion score (TPS) for PD-L1 staining was calculated considering membranous PD-L1 expression of tumour cells, independently of the intensity of the staining [7] (link). Following European medicines agency guidelines, positivity of PD-L1 expression was defined as TPS ≥ 1% and TPS ≥ 50%. Positive control was present on each slide, and samples with ≤30 tumour cells were excluded from analysis.
10
PD-L1 Expression and Genetic Profiling in Tumors
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
PD‐L1 immunohistochemistry was performed on a 4‐μm‐thick section of a formalin fixed, paraffin embedded tissue section of the primary tumor using 22C3 antibody (Agilent Technologies) and the tumor proportion score (TPS) was evaluated (SRL Inc.). The PD‐L1 expression was regarded as high when the TPS value was ≥50%.11 EGFR mutation and ALK rearrangement were examined when the tumor contained an adenocarcinoma component. EGFR mutation was examined using Cycleave‐PCR (SRL Inc.) from genomic DNA extracted from the primary tumor and ALK rearrangement was screened using Optiview ALK (D5F3, Roche Diagnostics) on serial sections from the primary tumor and was then confirmed by fluorescent in situ hybridization (SRL Inc.).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!